Highlights
- •Study aimed at utilizing artificial intelligence (AI)-based volumetric analysis on routine unstandardized T2-FLAIR scans in a multi-center study of 1002 people with relapsing-remitting MS (pwRRMS).
- •After propensity matching untreated pwRRMS had significantly greater 2-year thalamic atrophy when compared to treated pwRRMS (−1.2% vs. −0.3%, p = 0.044).
- •PwRRMS treated with high-efficacy DMTs had two-fold lower central atrophy rate when compared to pwRRMS treated on moderate-efficacy DMTs (3.5% vs. 7.0%, p = 0.001).
- •Non-harmonized MRI scans acquired through routine MS care can be utilized for measuring the neuroprotective DMT effect in a real-world setting.
Abstract
Background
Methods
Results
Conclusions
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersReferences
- Multiple sclerosis.Lancet. 2018; 391: 1622-1636
- MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.Nat. Rev. Neurol. 2020; 16: 171-182
- Imaging outcome measures for progressive multiple sclerosis trials.Mult. Scler. 2017; 23: 1614-1626
- Thalamic damage and long-term progression of disability in multiple sclerosis.Radiology. 2010; 257: 463-469
- Thalamic atrophy is associated with development of clinically definite multiple sclerosis.Radiology. 2013; 268: 831-841
- Deep gray matter volume loss drives disability worsening in multiple sclerosis.Ann. Neurol. 2018; 83: 210-222
- Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease.Ann. Neurol. 2018; 83: 223-234
- Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.Neurology. 2018; 90: e1324-e1332
- Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of Phase 3 ozanimod trials.Eur. J. Neurol. 2021; 28: 3722-3730
- Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study.Am. J. Neuroradiol. 2018; 39: 1480-1486
- Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.Mult. Scler. 2021; 27: 134-138
- Attention and processing speed performance in multiple sclerosis is mostly related to thalamic volume.Brain Imaging Behav. 2018; 12: 20-28
- Disability improvement is associated with less brain atrophy development in multiple sclerosis.AJNR Am. J. Neuroradiol. 2020; 41: 1577-1583
- Inter-scanner reproducibility of brain volumetry: influence of automated brain segmentation software.BMC Neurosci. 2020; 21: 35
- Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.Neuroimage Clin. 2017; 15: 769-779
- DeepGRAI (Deep gray rating via artificial intelligence): fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.Neuroimage Clin. 2021; 30102652
- Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.J. Neurol. Neurosurg. Psychiatry. 2022;
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Efficacy classification of modern therapies in multiple sclerosis.J. Comp. Eff. Res. 2021; 10: 495-507
- Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.Pract. Neurol. 2015; 15: 273-279
- Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.Neuroimage. 2002; 17: 479-489
- Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.Mult. Scler. 2022; 13524585221097561
- Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.Mult. Scler. 2022; 13524585221076717
- Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.Mult. Scler. 2020; 26: 312-321
- Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.Neuroimage Clin. 2020; 28102478
- Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset.J. Neuroimaging. 2022;
- Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes.Neuroimage Clin. 2021; 29102554
- Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: a multicenter study.Neuroimage Clin. 2021; 29102549
- Confounding by Indication in Clinical Research.JAMA. 2016; 316: 1818-1819
Article info
Publication history
Footnotes
DeepGRAI Registry Group:
Principal Investigator: R. Zivadinov.
Co-Principal Investigator: Michael G. Dwyer
Study Steering Committee: R. Zivadinov, D. Silva, J. Riolo, MG. Dwyer.
Bristol Myers Squib: D. Silva, J. Riolo.
MRI Analysis Center: R. Zivadinov, N. Bergsland, D. Jakimovski, MG. Dwyer, C. Suchan, Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
Study Sites:
Myassar Zarif and Mark Gudesblatt, Comprehensive Multiple Sclerosis Care Center, Patchogue, NY, USA, Mitch Freedman, Raleigh Neurology, Raleigh, NC; Samuel Hunter, Advanced Neurosciences Institute, Franklin, TN; Stanley Cohan, Providence Brain and Spine Institute, Portland, OR; Keith Edwards, MS Center of NE New York, Latham, NY; Brian Steingo, Infinity Clinical Research, LLC, Sunrise, FL; Rana Zabad, University of Nebraska Medical Center, Omaha, NE; Matthew Baker, Collier Neurologic Specialists, Naples, FL; Martin Belkin, Michigan Institute for Neurological Disorders (MIND), Farmington Hills, MI; Pavle Repovic, Swedish Neuroscience Institute, Seattle, WA; Amir Mazhari, Dent Neurology, Buffalo, NY, Abby Chase, Saunders Medical Center, Wahoo, NE; Jason Silversteen, Christiana Care Health Services, Inc., Newark, NJ; Derek Smith, Thames Neurological Institute, Norwich, CT; Donald Negroski, Negroski Neurology, LLP, Sarasota, Sarasota, FL; Marc Feinberg, SFM Clinical Research LLC, Boca Raton, FL; Stephen Newman, Island Neurological Association, Plainview, NY; Gabriel Pardo, Oklahoma Medical Research Foundation, Oklahoma City, OK; Evanthia Bernitsas, Department of Neurology, Wayne State University, Detroit, MI; Robert Krug, Mt. Sinai Rehabilitation Hospital, Hartford, CT; Peter Wade, Mercy Medical Center, Springfield, MA; Jennifer Ruiz, Saint Mary's Hospital, Waterbury, CT; Bhupendra Khatri, Center for Neurological disorders at Ascension St. Francis, Milwaukee, WI; Bradley Jabour, Medical Imaging Center of Southern California, West Hollywood, CA; Tarun Singhal, Sturdy Memorial Hospital MS Center, Attleboro, MA; Flavia Nelson and Adam Carpenter, University of Minnesota, Minneapolis, MN; Francesca Bagnato and Margareta Clarke, Vanderbilt University, Nashville, TN; Jaqueline Nicholas and Andrew Smith, Ohio Health, MS Center, Riverside Methodist Hospital, Columbus, OH; Barry Singer, MS Center for Innovations in Care, Missouri Baptist Medical, St. Louis, MO
Search terms: disease modifying therapy, multiple sclerosis, thalamic atrophy, whole brain atrophy, lateral ventricle volume
Study Funding:
Study was supported by a collaboration grant from Bristol Myers Squibb.
Statistical Analysis Performed by: Dejan Jakimovski; Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 100 High Street, Buffalo, NY 14,203, Email: [email protected]
